Cargando…
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
BACKGROUND: Current pulmonary hypertension treatment guidelines recommend use of a risk stratification model encompassing a range of parameters, allowing patients to be categorised as low, intermediate or high risk. Three abbreviated versions of this risk stratification model were previously evaluat...
Autores principales: | Humbert, Marc, Farber, Harrison W., Ghofrani, Hossein-Ardeschir, Benza, Raymond L., Busse, Dennis, Meier, Christian, Hoeper, Marius M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551213/ https://www.ncbi.nlm.nih.gov/pubmed/30923187 http://dx.doi.org/10.1183/13993003.02004-2018 |
Ejemplares similares
-
Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017) -
The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016) -
The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014) -
Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009) -
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)